Management of Mast Cell Activation Syndrome in Immunosuppressed Patients

Primary Recommendation: Oral Cromolyn Sodium

The American Academy of Allergy, Asthma, and Immunology recommends oral cromolyn sodium as the first-line treatment for mast cell activation syndrome, due to its ability to inhibit mediator release from mast cells without affecting immunity or gastric acid secretion, making it ideal for patients with constraints such as immunosuppression 1
The initial dose of cromolyn sodium should be 20-40 mg four times daily, titrated up gradually over weeks to reach a target of 200 mg four times daily, to improve tolerance and adherence, with a trial period of at least 1 month to determine efficacy 1, 3

The American Academy of Allergy, Asthma, and Immunology suggests omalizumab as a second-line consideration for refractory mast cell activation syndrome, which prevents anaphylactic episodes by binding free IgE and reducing mast cell activation threshold, with a mechanism that does not suppress immunity in the traditional sense 3
Omalizumab requires subcutaneous administration and is supported by case reports for preventing anaphylaxis, emergency visits, and lost work time, although it is expensive 3

The American Heart Association recommends training patients in immediate supine positioning at symptom onset, which is critical for hypotensive episodes, and providing an epinephrine autoinjector for severe reactions with throat tightness or angioedema 1, 2

The American Academy of Allergy, Asthma, and Immunology advises against introducing any new medication without a controlled setting and emergency equipment available, given the patient's history of throat tightness reactions, and warns that aspirin can trigger mast cell degranulation and should only be introduced in a controlled clinical setting 1, 2, 3
The American Academy of Allergy, Asthma, and Immunology also recommends avoiding compounding medications to eliminate additives, as this has not been proven beneficial and may delay appropriate treatment 1